Zepbound vs Saxenda
Tirzepatide vs Liraglutide for Weight Loss (2026)
Zepbound (tirzepatide) and Saxenda (liraglutide 3.0 mg) are both FDA-approved obesity injections — but they are a generation apart. Zepbound is a once-weekly dual agonist with much larger weight loss; Saxenda is an older once-daily GLP-1. Here's the comparison.
Zepbound vs Saxenda: At a Glance
- ✓Dual GLP-1/GIP receptor agonist
- ✓Once-weekly subcutaneous injection
- ✓FDA-approved for obesity and sleep apnea
- ✓SURMOUNT-1: ~20.9% weight loss at 72 weeks
- ✓Newer-generation, higher ceiling
- ✓Eli Lilly
- ✓GLP-1 receptor agonist
- ✓Once-daily subcutaneous injection
- ✓FDA-approved for weight management
- ✓SCALE: ~8% mean weight loss
- ✓Older liraglutide-based option
- ✓Novo Nordisk
Detailed Comparison
| Feature | Zepbound (Tirzepatide) | Saxenda (Liraglutide) |
|---|---|---|
| Generic | Tirzepatide | Liraglutide 3.0 mgBest |
| Manufacturer | Eli Lilly | Novo Nordisk |
| Mechanism | GLP-1 + GIP dual agonist | GLP-1 agonist |
| Frequency | Once weekly | Once daily |
| Indication | Obesity / sleep apnea | Obesity / weight management |
| Weight Loss | ~20.9% at 72 weeks | ~8% (SCALE) |
| Injections per Month | ~4 | ~30 |
| Generation | Newer dual agonist | Older single agonist |
| Side Effects | Nausea, diarrhea, constipation | Nausea, vomiting, diarrhea |
| Extra Indication | Obstructive sleep apnea | Adolescent weight management |
How to Choose
Maximum Weight Loss
Zepbound's ~20.9% dwarfs Saxenda's ~8%. For the most weight loss, tirzepatide is clearly stronger.
Fewer Injections
Zepbound is once weekly (~4 shots/month); Saxenda is once daily (~30/month). Weekly dosing is far more convenient.
Extra Indications
Zepbound carries an obstructive sleep apnea indication; Saxenda is approved for certain adolescents.
When Saxenda Fits
Saxenda may suit patients who can't access tirzepatide, need an adolescent option, or tolerate liraglutide better.
Tolerability
Both cause GI side effects. Daily liraglutide gives steadier exposure; weekly tirzepatide is more potent. Individual response varies.
Cost & Coverage
Both are costly without coverage. Insurance and savings programs often decide access. Check both.
Which Should You Choose?
On efficacy and convenience, Zepbound wins clearly. Tirzepatide's dual GLP-1/GIP mechanism produced roughly 20.9% weight loss at 72 weeks — more than double Saxenda's ~8% — and it's a once-weekly injection rather than a daily one. For most adults seeking maximum weight loss, Zepbound is the stronger choice.
Saxenda still has a role. It may be the option when tirzepatide isn't accessible or affordable, when an adolescent indication is needed, or when a patient tolerates liraglutide better. Daily dosing also gives some people a sense of steadier control.
If you're early in your decision, Zepbound (or weekly semaglutide, Wegovy) generally represents the current standard for potency. Whatever you take, track your dose, weight, and side effects in Shotlee — and if you switch from Saxenda to Zepbound, your history travels with you.
Zepbound vs Saxenda: Frequently Asked Questions
Zepbound (tirzepatide) is substantially stronger — about 20.9% weight loss at 72 weeks versus roughly 8% for Saxenda (liraglutide). Zepbound is also once weekly instead of daily.
Zepbound is tirzepatide, a once-weekly dual GLP-1/GIP agonist. Saxenda is liraglutide 3.0 mg, an older once-daily GLP-1. Both are FDA-approved for weight management, but Zepbound produces much more weight loss.
Saxenda may be chosen when tirzepatide isn't accessible or affordable, when an adolescent weight-management option is needed, or when a patient tolerates liraglutide better. For maximum weight loss, Zepbound is stronger.
Zepbound is once weekly (about 4 injections per month). Saxenda is once daily (about 30 per month). Weekly dosing is more convenient for most people.
Yes. Shotlee tracks both daily and weekly injections, with dose logs, weight trends, and side-effect tracking — handy if you switch between them.
Track Zepbound or Saxenda in Shotlee
Free dose logging, weight trends, and side-effect tracking for daily or weekly injections.
📚References & sources
Latest on Zepbound
Beyond the Hype: Navigating the Rise of Online Peptides
A surge in injectable peptides marketed online for enhancement purposes is outpacing regulatory oversight, creating a 'grey zone' with potential public health implications. This article delves into the complexities, risks, and what consumers should understand.
6 min read
Beyond the Scale: GLP-1 Users & the Exercise Paradox
While GLP-1 medications have revolutionized weight loss, a recent study indicates a concerning trend: users may be reducing their physical activity. This article explores the findings and emphasizes the continued importance of exercise.
7 min read
Ozempic, Wegovy & Mounjaro: Navigating Dizziness and Fainting Risks
Recent research highlights a potential safety concern with GLP-1 medications, linking them to an increased risk of dizziness and fainting, particularly in certain patient groups. Discover what this means for your health.
6 min read